Because recurrent mutations in the players of the Wnt pathway have not been reported thus far, it would be interesting to decipher how mutations in the genes leading to MPNST progression (i.e., CDKN2A, EED, SUZ12) activate the Wnt pathway, and whether these mechanisms can yield novel biomarkers of tumor stages. This evidence concerns the gene EED and malignant peripheral nerve sheath tumor.